EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection

Stefan Borov iD, Benito Baldauf iD, Jana Henke, Herribert Pavaci iD, Arben Perani, Bernhard Zrenner iD, Josef Dietl, Julinda Mehilli iD, Ernest W Lau, Reinhard Vonthein iD, Hendrik Bonnemeier iD

Europace · 2023

DOI: 10.1093/europace/euad306 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Europace, 2023. Verfasst von Stefan Borov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Klinikum Freising, Alois-Steinecker-Straße 18, Freising 85354, Germany. Hauptthemen laut MEDLINE: Anti-Infective Agents, Defibrillators, Implantable, Heart Diseases, Pacemaker, Artificial. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TauroPace™., TauroPace™.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. Methods and results The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802).

Conclusion

TauroPace is safe but more effective than H2O2 in reducing CIED infection. Clinical trial registration ClinicalTrials.gov Identifier: NCT05576194

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Infective AgentsDefibrillators, ImplantableHeart DiseasesPacemaker, ArtificialProsthesis-Related InfectionsHumansHydrogen PeroxideProspective StudiesTaurineThiadiazines

Stichwörter der Autor:innen

Cardiac implantable electronic deviceHydrogen peroxideInfectionTaurolidineTauropace

Substanzen

Anti-Infective AgentsHydrogen PeroxidetaurolidineTaurineThiadiazines

Autor:innen und Institutionen

  • Department of Cardiology, Klinikum Freising, Alois-Steinecker-Straße 18, Freising 85354, Germany.
  • Medical Faculty, Christian-Albrechts University, Christian-Albrechts-Platz 4, Kiel 24118, Germany.
  • Institute of Life Science, Hochschule Bremerhaven, An der Karlstadt 8, Bremerhaven 27568, Germany.
  • Krankenhaus Landshut Achdorf, Achdorfer Weg 3, Landshut 84036, Germany.
  • Department of Cardiology, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BA, UK.
  • Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.

ORCID-Profile: Stefan Borov, Benito Baldauf, Herribert Pavaci, Bernhard Zrenner, Julinda Mehilli, Reinhard Vonthein, Hendrik Bonnemeier

Förderung

  • TauroPace™.
  • TauroPace™

Zitieren

APA

Borov, S., Baldauf, B., Henke, J., Pavaci, H., Perani, A., Zrenner, B., Dietl, J., Mehilli, J., Lau, E. W., Vonthein, R., & Bonnemeier, H. (2023). Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. Europace. https://doi.org/10.1093/europace/euad306

Vancouver

Borov S, Baldauf B, Henke J, Pavaci H, Perani A, Zrenner B, et al. Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. Europace. 2023. doi:10.1093/europace/euad306

BibTeX
@article{Borov2023,
  author = {Borov, Stefan and Baldauf, Benito and Henke, Jana and Pavaci, Herribert and Perani, Arben and Zrenner, Bernhard and Dietl, Josef and Mehilli, Julinda and Lau, Ernest W and Vonthein, Reinhard and Bonnemeier, Hendrik},
  title = {Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad306}
}
Kostenlos starten →